

- (21) Application No **7925674**  
(22) Date of filing **24 Jul 1979**  
(23) Claims filed **24 Jul 1979**  
(30) Priority data  
(31) **928668**  
(32) **28 Jul 1978**  
(33) **United States of America (US)**  
(43) Application published  
**6 Feb 1980**  
(51) **INT CL<sup>3</sup>**  
**C07C 149/42**  
**A61K 31/135**  
(52) Domestic classification  
**C2C 220 227 22Y 29X 29Y**  
**30Y 313 31Y 322 32Y 339**  
**364 36Y 373 37Y 464 613**  
**620 624 650 662 802 80Y**  
**AA QN RN**  
(56) Documents cited  
**GB 1451180**  
**GB 1137764**  
(58) Field of search  
**C2C**  
(71) Applicant  
**Bristol-Myers Company,**  
**345 Park Avenue,**  
**New York,**  
**State of New York 10022,**  
**United States of America.**  
(72) Inventor  
**Duane F Morrow**  
(74) Agents  
**Boult, Wade & Tennant.**

(54) **Alkylthiophenoxyalkylamines**

(57) A new class of alkylthiophenoxyalkylamine derivatives and methods for their preparation are described. The compounds have vasodilating and anti-spasmodic activity, inhibit blood platelet aggregation and are substantially free of *beta*-adrenergic blocking effects. They are particularly valuable in the treatment of disease states responsive to vasodilation such as obstructive peripheral vascular diseases and cerebral vascular deficiencies and can be incorporated into pharmaceutical and veterinary formulations. Representative and preferred embodiments of the invention are N-[3-[4-(methylthio)phenoxy]propyl]octylamine and N-[3-[4-(1-methylethyl)-thio]phenoxy]propyl]octylamine.

## SPECIFICATION

## Alkylthiophenoxyalkylamines

5 This invention pertains to carbon compounds having drug and bio-affecting properties. It is particularly 5  
concerned with new and useful alkylthiophenoxyalkylamines, use thereof in pharmaceutical preparations  
and therapeutic methods, and process for producing the alkylthiophenoxyalkylamines. The alkylthiophenoxyalkylamines of this invention increase peripheral blood flow, relax vascular smooth muscle, and inhibit  
10 peripheral vascular disease such as intermittent claudication and cerebro-vascular deficiencies associated 10  
with arteriosclerosis.


As used herein, the term "lower alkyl" refers to a carbon chain comprised of both straight and branched chain carbon radicals of 1 to 4 carbon atoms inclusive. Exemplary of these carbon chain radicals are methyl, ethyl, propyl, isopropyl, 1-butyl, 1-methylpropyl, 2-methyl-propyl, and *tert.*-butyl.

15 As used herein, the term "alkyl" refers to straight or branched chain carbon radicals with the number of 15  
carbon atoms comprising the particular alkyl radical specifically designated or referred to by standard notations such as (C<sub>1</sub>-C<sub>4</sub>), (C<sub>1</sub>-C<sub>8</sub>) and (C<sub>6</sub>-C<sub>12</sub>).

As used herein, the term "non-toxic pharmaceutically acceptable acid addition salts" refers to salts of 20  
compounds of formula I formed with a variety of inorganic and organic acids, the anions of which are 20  
relatively non-toxic. Such acid addition salts are considered pharmacologically equivalent to the bases characterized by structural formula I. Examples of useful salt forming acids are acetic, lactic, succinic, maleic, tartaric, citric, gluconic, ascorbic, benzoic, cinnamic, fumaric, sulfuric, phosphoric, hydrochloric, hydrobromic, hydroiodic, sulfamic, sulfonic acids such as methanesulfonic, benzenesulfonic, *p*-toluenesulfonic, and related acids. Acid addition salts of this invention may be prepared and isolated by conventional means; for 25  
instance, by treating a solution or suspension of the free base in a reaction inert solvent with the desired acid 25  
and recovering the salts which form by concentration under reduced pressure or by crystallization techniques or other standard chemical manipulations. Acid addition salts which are somewhat toxic and therefore do not meet the foregoing criteria for pharmaceutical acceptability are sometimes useful as intermediates for isolation and purification of the bases of formula I or for other chemical purposes such as 30  
separation of optical isomers. Such salts are also considered part of this invention. 30

Variously substituted phenoxyalkylamines with a broad spectrum of biological activity are known. For example, A. Burger, *Medicinal Chemistry*, 2nd Edition (Interscience, New York), page 600 lists the following *beta*-phenoxyethylamines.

35 35




40 *Nuclear Substituent* *R* *Activity* 40

None	piperidine	antipyretic	
3-OH	methyl	pressor	
None	ethyl	sympatholytic	
45 4-NH <sub>2</sub>	methyl	nicotinic	45
2-isopropyl-5-methyl	ethyl	antihistaminic	
2-allyl-6-OCH <sub>3</sub>	ethyl	oxytotic	
2-phenyl	ethyl	antifibrillant	

50 50

Pinhas, U.S. Patent No. 3,873,620 patented March 25, 1975 discloses phenoxyalkylamines of the formula

55 55




60 in which n is zero or 1, R is hydrogen or hydroxy, R<sub>2</sub> is hydrogen, hydroxy (R<sub>2</sub> being other than hydroxy when 60  
n is zero) or alkyl and A is CH<sub>2</sub>OH, COR<sup>1</sup>, or CH(OH)R<sup>1</sup> in which R<sup>1</sup> is cyclohexyl or phenyl. The compounds are said to be useful as coronary vasodilators and antispasmodics.

No examples of prior art phenoxyethylamines or phenoxypropylamines having a nuclear alkylthio substituent in combination with an alkylamino moiety are known to the applicant.

65 Broadly described, the present invention is directed to novel alkylthiophenoxyalkylamines of the formula 65

5



5

10 wherein R is hydrogen or lower alkyl of 1 to 4 carbon atoms inclusive; R<sub>1</sub> is alkyl of 1 to 8 carbon atoms inclusive; R<sub>2</sub> is alkyl of 6 to 12 carbon atoms inclusive; n is the integer 2 or 3; and the pharmaceutically or veterinarily acceptable and other acid addition salts thereof.


10

This invention is also concerned with pharmaceutical compositions containing the alkylthiophenoxyalkylamines and further contemplates methods for both producing as well as employing the compounds and compositions therapeutically for the treatment of peripheral vascular disease, other degenerative conditions

15

15 of the vascular system such as atherosclerosis and other thrombogenic conditions. The alkylthiophenoxyalkylamines provided by this invention are represented by formula I

20



20

25 wherein

25


R is hydrogen or lower alkyl of 1 to 4 carbon atoms inclusive;  
 R<sub>1</sub> is alkyl of 1 to 8 carbon atoms inclusive;  
 R<sub>2</sub> is alkyl of 6 to 12 carbon atoms inclusive;  
 n is the integer 2 or 3;

30 and the pharmaceutically or veterinarily acceptable acid addition salts thereof.

30

According to one aspect of the instant invention, there is provided a process for preparing an alkylthiophenoxyalkylamine of formula I comprising reacting an alkali metal salt of an alkylthiophenol derivative of formula II

35




35

40

wherein R and R<sub>1</sub> have meanings hereinabove described with 1-bromo-2-chloroethane or 1-bromo-3-chloropropane affording a phenoxyalkyl chloride intermediate of formula III

40

45




45

50

wherein R, R<sub>1</sub> and n have meanings hereinabove described, and condensing the formula III intermediate with an amine of formula IV

50

55



55

wherein R<sub>2</sub> has the meaning hereinabove described; whereafter, if desired, the formula I product in free base form is reacted with an acid to form an acid addition salt thereof.

In carrying out the foregoing process, formula II alkylthiophenol alkali metal salts may be prepared in conventional manner. For instance, the alkylthiophenol is treated with a suitable alkali metal base such as sodium hydroxide or potassium hydroxide in a reaction inert solvent such as isopropanol, ethanol, and the like. Other standard methods for preparing phenolic alkali metal salts may be employed such as treating the formula II phenol with alkali metal hydrides, e.g. sodium or potassium hydride, in an inert reaction solvent such as 1,2-dimethoxy-ethane or with an alkali metal alkoxide such as sodium methoxide in a lower alkanol solvent such as methanol, isopropanol and the like.

65 Condensation of the formula II alkylthiophenol alkali metal salt with 1-bromo-2-chloroethane or

65

1-bromo-3-chloropropane to provide alkylthiophenoxyalkyl chlorides of formula III is carried out at moderately high temperatures, e.g., between about 50°C. and the reflux temperature of the reaction medium, generally for periods of from 10 to 72 hours.

5 Condensation of formula III alkylthiophenoxyalkyl chlorides with R<sub>2</sub>-NH<sub>2</sub> amines of formula IV is preferably carried out in the presence of an organic solvent inert under the reaction conditions. Elevated temperature, e.g., the reflux temperature of the solvent, is employed to complete the reaction. Suitable solvents include acetonitrile and lower alkanols such as methanol, ethanol, propanol, isopropanol, and the like. Excess amine or an alkali metal carbonate such as sodium or potassium carbonate may be employed to take up HCl formed during the reaction. In the absence of a suitable acid acceptor, a catalytic amount of potassium iodide is preferably employed. The condensation can also be effected in the absence of a reaction solvent by employing a sufficient amount of the amine reactant to serve as the reaction medium. 10

The required formula II alkylthiophenols are obtained by coupling a diazotized aminophenol with an alkyl mercaptan to form a diazosulfide which is then decomposed providing the corresponding alkylthiophenol. This is a conventional method and adaptations thereof are described in R.B. Wagner, and H.D. Zook, 15 *Synthetic Organic Chemistry*, page 789 (1953 Wiley); E. Miller, et al., *J. Am. Chem. Soc.*, 55, 1224 (1933); S. Asaka, et al., *Chem. Abst.* 61, 13243a. 15

Suitable Alkylthiophenol reactants of formula II which may be employed in the present process include:

20 4-methylthiophenol,  
4-ethylthiophenol,  
4-*n*-propylthiophenol,  
4-*n*-butylthiophenol,  
4-*n*-pentylthiophenol,  
4-*n*-hexylthiophenol,  
25 4-*n*-heptylthiophenol,  
4-*n*-octylthiophenol,  
4-isopropylthiophenol,  
4-(3-methylbutylthio)phenol,  
2-*n*-butylthiophenol,  
30 3-*n*-butylthiophenol,  
2-ethylthiophenol,  
2-*n*-propylthiophenol,  
2-isopropylthiophenol,  
3-ethylthiophenol,  
35 3-*n*-propylthiophenol,  
3-isopropylthiophenol,  
2-methyl-4-(methylthio)phenol,  
3-methyl-4-(methylthio)phenol.

40 Suitable amines of formula IV which may be employed in the present process include: 40

*n*-hexylamine,  
*n*-heptylamine,  
*n*-octylamine,  
45 *n*-nonylamine,  
*n*-decylamine,  
*n*-undecylamine,  
*n*-dodecylamine,  
*n*-isoactylamine,  
50 2,2-dimethylhexylamine,  
1,1-dimethylheptylamine. 50

As stated hereinabove, the alkylthiophenoxyalkylamines of the present invention increase peripheral blood flow, relax vascular smooth muscle, and inhibit blood platelet aggregation. The compounds are substantially free of *beta*-adrenergic blocking effects which inhibit peripheral vasodilating activity of *beta*-adrenergic stimulatory endogenous amines. Standard *in vivo* and *in vitro* pharmacological test methods can be employed in assessing the activity of compounds characterized by formula I. For instance, the perfused dog hind limb preparation is considered particularly useful in measuring vasodilator activity. The preferred compounds N-[3-[4-(methylthio)phenoxy]propyl]octylamine hydrochloride and N-[3-[4-[(1-methylethyl)thio]phenoxy]propyl]octylamine hydrochloride, which produce a 50 mm Hg fall in perfusion pressure at infusion doses of 0.7 and 0.32 mg./min., respectively, are representative of the activity of the compounds of the instant invention in this test. Papaverine, a well-known vasodilating agent, reduces pressure by a 50 mm Hg at an infusion dose of 0.76 mg./min. Antispasmodic activity is determined by spasmogen-challenged rabbit aortic strip with antithrombogenic action demonstrated by inhibition of adenosine diphosphate and collagen-induced platelet aggregation in human platelet-rich plasma. The 65

isoproterenol challenged guinea pig trachea test, which is standard in the art, is suitable for measuring *beta*-adrenergic blocking action.

Another aspect of the instant invention concerns a therapeutic process for treating a mammal requiring vasodilation which comprises systemically administering to the mammal an effective vasodilating amount of a compound having formula I or pharmaceutically acceptable non-toxic acid addition salt thereof.

As used herein, the term "effective vasodilating amount" is intended to mean a dose which exerts a vasodilator effect in the effected mammal without untoward side effects.

By systemic administration, it is intended to include both oral and parenteral routes. Examples of parenteral administration are intramuscular, intravenous, intraperitoneal, rectal, and subcutaneous administration. In rectal administration, both ointments and suppositories may be employed. While the dosage will vary to some extent with the mode of administration and the particular compound chosen, from about 0.5 mg. per kg. body weight to 25 mg. per kg. body weight of a compound having formula I or non-toxic pharmaceutically acceptable salts thereof administered in effective single or multiple dosage units generally provides the desired vasodilating effect.

In carrying out the therapeutic process of the instant invention, the formula I compounds are generally administered for vasodilating purposes in the form of a pharmaceutical preparation containing either a formula I free base or a pharmaceutically acceptable non-toxic acid addition salt thereof as the active component in combination with a pharmaceutically acceptable carrier. The carrier may be solid, semi-solid, liquid diluent or a capsule. Accordingly, a further feature of the instant invention is directed to pharmaceutical compositions containing the compounds of formula I or non-toxic pharmaceutically acceptable acid addition salts thereof in combination with a pharmaceutically acceptable carrier.

For the preparation of pharmaceutical compositions containing the compounds of formula I in the form of dosage units for oral administration, the compound is mixed with a solid, pulverulent carrier, (e.g. lactose, sucrose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives, or gelatin) as well as with an anti-friction agent (e.g. magnesium stearate, calcium stearate, polyethylene glycol waxes or the like) and pressed into tablets. The tablets may be used uncoated or coated by conventional techniques to delay disintegration and absorption in the gastrointestinal tract thereby providing a sustained action over a longer time period. If coated tablets are desired, the above prepared core may be coated with a concentrated solution of sugar, which solution may contain, e.g., gum, arabic, gelatin, talc, titanium dioxide, or the like. Furthermore, tablets may be coated with a lacquer dissolved in an easily volatile organic solvent or mixture of solvents. If desired, dye may be added to this coating.

In the preparation of soft gelatin capsules or in the preparation of similar closed capsules, the active compound is mixed with a vegetable oil. Hard gelatin capsules may contain granules of the active ingredient in combination with a solid, pulverulent carrier such as lactose, saccharose, sorbitol, starch, (e.g., potato starch, corn starch, or amylopectin), cellulose derivatives or gelatin.

Dose units for rectal administration may be prepared in the form of suppositories containing the active substance of formula I in mixture with a neutral fat base, or they may be prepared in form of gelatin-rectal capsules containing the active substance in a mixture with a vegetable oil or paraffin oil.

Liquid preparations for oral administration may be present in the form of elixirs, syrups or suspensions containing from about 0.2% by weight to about 20% by weight of the active ingredient. Such liquid preparations may contain coloring agents, flavoring agents, sweetening agents, and carboxymethylcellulose as a thickening agent.


Suitable solutions for parenteral administration by injection may be prepared as an aqueous solution of a water-soluble pharmaceutically acceptable salt of the compounds of formula I adjusted to a physiologically acceptable pH. These solutions may also contain stabilizing agents.

Pharmaceutical tablets for oral use are prepared by conventional methods involving mixing the therapeutic compound of formula I and necessary auxiliary agents.

The following examples are given solely for the purpose of illustration and are not to be construed as limitations of this invention, many variations of which are possible without departing from the spirit or scope thereof.

#### EXAMPLE 1

*N*-[3-[4-(Methylthio)phenoxy]-propyl]octylamine Hydrochloride




(a) A solution of 4-(methylthio)phenol (10.0 g, 0.071 mole) in 150 ml. of 1,2-dimethoxyethane is added to a slurry of a 57% dispersion of sodium hydride (3.0 g., 0.071 mole) in mineral oil (previously washed with hexane to remove the mineral oil) in 100 ml. of 1,2-dimethoxyethane. After the initial reaction is complete, 1-bromo-3-chloropropane (12.63 g., 0.08 mole) is added in one portion. The resulting mixture is stirred and refluxed for a period of 68 hrs., cooled and then concentrated under reduced pressure. Residual material (oil) is dissolved in ether and washed with water. The ether solution (after drying over magnesium sulfate) is

concentrated under reduced pressure to provide 14.6 g. of an oil containing approximately 25% starting phenol according to NMR spectra. Distillation of the oil under reduced pressure affords, after a forerun of 4-(methyl-mercapto)phenol, 5.0 g. (32% yield) of 1-chloro-3-[4-(methylthio)phenoxy]propane, b.p. 150-152°C. at 27 mm Hg.

- 5 b) A solution of 1-chloro-3-[4-(methylthio)-phenoxy]propane (5.0 g., 0.023 mole) in 30 ml. of ethanol is treated with *n*-octylamine (2.84 g., 0.022 mole) and 30 mg. of potassium iodide. After refluxing for a period of 18 hrs., the reaction mixture is concentrated to dryness under reduced pressure, treated with 3N potassium hydroxide solution and ether, and the layers separated. The ether layer is washed with water, concentrated under reduced pressure, and heated on a steam bath at 0.1 mm Hg pressure to remove residual *n*-octylamine. The residue of N-[3-[4-(methylthio)phenoxy]propyl]octylamine base thus obtained is dissolved in ethanol, treated with excess 6N hydrochloric acid and activated charcoal, filtered and concentrated to dryness under reduced pressure. Crystallization of the residue from isopropyl alcohol-ether affords 1.7 g. (22% yield) of analytically pure N-[3-[4-(methylthio)phenoxy]propyl]octylamine hydrochloride, m.p. 214.5-215.5°C. (corr.).
- 15 *Anal.* Calcd. for  $C_{18}H_{31}NOS \cdot HCl$ : C, 62.49; H, 9.32; N, 4.05.  
Found: C, 62.44; H, 9.36; N, 3.90.

### EXAMPLE 2

20 *N*-[3-[4-[(1-Methylethyl)thio]-phenoxy]propyl]octylamine Hydrochloride




- 25 (a) A solution of 4-(1-methylethylthio)phenol (16.83 g., 0.1 mole) in 150 ml. of isopropyl alcohol is treated with 5.2 ml. of 50% sodium hydroxide solution (0.10 mole) and 2 ml. of water. To this mixture is added in one portion 1-bromo-3-chloropropane (16.5 g., 0.105 mole) and the mixture stirred and refluxed for a period of 20 hrs. After cooling, the reaction mixture is concentrated under reduced pressure and the resulting residue extracted with ether. The ethereal extract is filtered, concentrated under reduced pressure and the oily residue distilled affording 4.8 g. (20% yield) of 1-chloro-3-[4-(1-methylethylthio)phenoxy]propane, b.p. 136-140°C. at 0.6 mm Hg.
- 30 (b) A mixture of 1-chloro-3-[4-(1-methylethylthio)phenoxy]propane (4.8 g., 0.02 mole), *n*-octylamine (2.53 g., 0.02 mole), potassium carbonate (5.42 g., 0.039 mole) in 150 ml. of acetonitrile is stirred and refluxed for a 23 hr. period. The cooled reaction mixture is filtered and the filtrate concentrated under reduced pressure to provide an oil. The oily residue is dissolved in ether, filtered and concentrated again to an oil. Unreacted *n*-octylamine is removed by distillation (heating the oil 80°C. at 0.1 mm Hg). Residual material is dissolved in ether and treated with excess ethanolic hydrogen chloride to provide the insoluble hydrochloride salt.
- 40 Crystallization of the salt from isopropyl alcohol-ether affords 1.63 g. (22% yield) of N-[3-[4-[(1-methylethyl)thio]phenoxy]propyl]octylamine hydrochloride, m.p. 193.5-195.5°C. (corr.).

*Anal.* Calcd. for  $C_{20}H_{35}NOS \cdot HCl$ : C, 64.23; H, 9.70; N, 3.74.  
Found: C, 64.34; H, 9.70; N, 3.58.

### EXAMPLE 3

50 *N*-[3-[4-[(1-Methylethyl)thio]-phenoxy]propyl]-2,2-dimethylhex-1-ylamine



- 55 (a) *2,2-dimethylhex-1-ylamine.* A solution of capronitrile (25 g., 0.26 mole) and methyl iodide (75 g., 0.53 mole) in 80 ml. of dry toluene is warmed to 80° and treated gradually with a suspension of sodium amide (25.4 g., 0.65 mole) in 100 ml. of toluene at a rate sufficient to maintain general reflux. After addition is complete, the mixture is stirred and refluxed for an additional 2 hr. period, cooled and treated with 150 ml. of water. The organic layer is separated, washed with water and dried over magnesium sulfate. Concentration of the dried solution under reduced pressure and distillation of residual material affords an 81% yield of 2,2-dimethylcapronitrile.
- 60 A solution of 2,2-dimethylcapronitrile (10.0 g., 0.078 mole) in 100 ml. of ether is added slowly to a suspension of lithium aluminum hydride (6.0 g., 0.158 mole) in 200 ml. of ether while maintaining the reaction at 0-5°. After stirring the reaction mixture for an additional 2 hr., at 0.5°, the mixture is hydrolyzed by sequentially adding 6.0 ml. of water, 6.0 ml. of 15% sodium hydroxide solution, and finally 18 ml. of water.
- 65 The hydrolyzed mixture is stirred for an additional hour, filtered and the ether phase concentrated under

reduced pressure. Distillation of residual material provides 2,2-dimethylhex-1-ylamine.

(b) Reaction of 1-chloro-3-[4-(1-methylethyl-thio)phenoxy]propane with 2,2-dimethylhex-1-ylamine according to the procedure of Example 2(b) and conversion of the base to the hydrochloride provides N-[3-[4-(1-methylethyl)thio]phenoxy]propyl]-2,2-dimethylhex-1-ylamine hydrochloride.


5

## EXAMPLE 4

5

*N*-[3-[4-[(1-Methylethyl)thio]phenoxy]propyl]-2-methyl-2-octylamine Hydrochloride

10



10

(a) *2-Methyl-2-octanol*.- A solution of methyl-heptanoate (14.5 g., 0.1 mole) in 200 ml. of ether is added to 200 ml. of 3*M* solution (0.6 mole) of methyl magnesium bromide in ether at a rate sufficient to maintain refluxing. After addition is complete, the resulting mixture is refluxed for 1 hr. and then stirred at 26° for a 16 hour period. The mixture is hydrolyzed by the addition of dilute ammonium chloride solution, filtered and the filter cake dissolved in 2*N* hydrochloric acid and extracted with ether. The ethereal extract and filtrate are combined, sequentially washed with water, dilute sodium bicarbonate solution and brine and dried over magnesium sulfate. Concentration of the dried solution and distillation of residual material under reduced pressure provides 13.1 g. (91% yield) of 2-methyl-2-octanol, b.p. 130° (100 mm Hg).

(b) *N*-(2-Methyl-2-octyl)acetamide.- A solution of concentrated sulfuric acid (5.55 g., 0.055 mole) in 32 ml. of glacial acetic acid is treated with acetonitrile (2.5 g., 0.016 mole) and 2-methyl-2-octanol (8.0 g., 0.055 mole) and the resulting mixture stirred at 26° for a 17 hr. period. After diluting with 125 ml. of water, the mixture is extracted with ether and the ethereal extract sequentially washed with water, dilute sodium bicarbonate solution and brine and dried over magnesium sulfate. Concentration of the dried solution provides 8.7 g. (85% yield) of *N*-(2-methyl-2-octyl)acetamide which is used in the next step without further purification.

(c) *2-methyl-2-octylamine*.- A solution of potassium hydroxide (10.0 g., 0.18 mole) in 100 ml. of ethylene glycol is treated with *N*-(2-methyl-2-octyl)acetamide (13.0 g., 0.07 mole) and the mixture heated at 200° for a 64 hr. period. The reaction mixture is diluted with 400 ml. of water and extracted with ether. The ethereal extract is washed with water and brine and then dried over sodium sulfate. Concentration of the dried solution under reduced pressure affords 10.4 g. (62% yield) of 2-methyl-2-octylamine which is used in the next step without further purification.

(d) *N*-[3-[4-[(1-Methylethyl)thio]thio]phenoxy]-propyl]-2-methyl-2-octylamine Hydrochloride Preparation.- Reaction of 1-chloro-3-[4-(1-methylethylthio)phenoxy]propane with 2-methyl-2-octylamine according to the procedure of Example 2(b) and conversion of the base to the hydrochloride provides *N*-[3-[4-(1-methylethyl)thio]phenoxy]-propyl]-2-methyl-2-octylamine hydrochloride.


40

## EXAMPLE 5

40

*N*-[2-[4-[(1-methylethyl)thio]phenoxy]ethyl]octylamine Hydrochloride

45



45

According to the procedure of Example 1, 1-chloro-2-[4-(methylthio)phenoxy]ethane from 4-(methylthio)phenol and 1-chloro-2-bromoethane is reacted with *n*-octylamine to provide *N*-[2-[4-(1-methylethyl)thio]phenoxy]ethyl]octylamine hydrochloride.

50


## EXAMPLE 6

The following compounds of Table A are prepared according to the procedures of Examples 1 and 2 by reacting the alkylthiophenoxypropyl chloride intermediate obtained from the starting phenol and 1-bromo-3-chloro-propane with *n*-octylamine.

55

55

TABLE A



5

5

Example	Starting Thiophenol	Product		
		R	R <sub>1</sub> S	
6	4-ethylthiophenol	H	4-C <sub>2</sub> H <sub>5</sub> S	
7	4-n-propylthiophenol	H	4-n-C <sub>3</sub> H <sub>7</sub> S	
8	4-n-butylthiophenol	H	4-n-C <sub>4</sub> H <sub>9</sub> S	
9	4-n-pentylthiophenol	H	4-n-C <sub>5</sub> H <sub>11</sub> S	
10	4-n-hexylthiophenol	H	4-n-C <sub>6</sub> H <sub>13</sub> S	15
11	4-n-heptylthiophenol	H	4-n-C <sub>7</sub> H <sub>15</sub> S	
12	4-n-octylthiophenol	H	4-n-C <sub>8</sub> H <sub>17</sub> S	
13	4-(3-methylbutylthio)phenol	H	4-(CH <sub>3</sub> ) <sub>2</sub> CHCH <sub>2</sub> CH <sub>2</sub> S	
14	2-n-butylthiophenol	H	2-n-C <sub>4</sub> H <sub>9</sub> S	
15	3-n-butylthiophenol	H	3-n-C <sub>4</sub> H <sub>9</sub> S	20
16	2-ethylthiophenol	H	2-C <sub>2</sub> H <sub>5</sub> S	
17	2-n-propylthiophenol	H	2-n-C <sub>3</sub> H <sub>7</sub> S	
18	2-isopropylthiophenol	H	2-i-C <sub>3</sub> H <sub>7</sub> S	
19	3-ethylthiophenol	H	3-C <sub>2</sub> H <sub>5</sub> S	
20	3-n-propylthiophenol	H	3-n-C <sub>3</sub> H <sub>7</sub> S	25
21	3-isopropylthiophenol	H	3-i-C <sub>3</sub> H <sub>7</sub> S	
22	2-methyl-4-(methylthio)-phenol	2-CH <sub>3</sub>	4-CH <sub>3</sub> S	
23	3-methyl-4-(methylthio)-phenol	3-CH <sub>3</sub>	4-CH <sub>3</sub> S	

30

30

## EXAMPLE 24

## Tablets

35 The following ingredients are blended into proportion by weight indicated according to conventional pharmaceutical techniques to provide a tablet base. 35

	Ingredient	Amount	
40	Lactose	79	40
	Corn starch	10	
	Talcum	6	
	Tragacanth	4	
	Magnesium stearate	1	

45

45

This tablet base is blended with sufficient N-[3-[4-[(1-methylethyl)thio]phenoxy]propyl]octylamine hydrochloride to provide tablets containing 10, 20, 40, 80, 160 and 320 mg. of active ingredient and compressed into conventional tablet press.

50

50

## EXAMPLE 25

## Dry-filled Capsules

55 The following ingredients are blended in a conventional manner in the proportion by weight indicated. 55

	Ingredient	Amount	
60	Lactose, U.S.P.	50	60
	Starch	5	
	Magnesium stearate	2	

60

60

65 Sufficient N-[3-[4-[(1-methylethyl)thio]phenoxy]propyl]octylamine hydrochloride is added to the blend to provide capsules containing 10, 20, 40, 80, 160 and 320 mg. of active ingredient which is filled into hard 65


65



gelatin capsules of a suitable size.

CLAIMS

5 1. A compound of the formula /:



10 wherein R is hydrogen or C<sub>1</sub> to C<sub>4</sub> alkyl; R<sub>1</sub> is C<sub>1</sub> to C<sub>8</sub> alkyl; R<sub>2</sub> is C<sub>6</sub> to C<sub>12</sub> alkyl; n is 2 or 3; or a pharmaceutically or veterinarily acceptable acid addition salt thereof.

15 2. N-[3-[4-(methylthio)phenoxy]propyl]octylamine of a pharmaceutically or veterinarily acceptable salt thereof.

3. N-[3-[4-(methylthio)phenoxy]propyl]octylamine hydrochloride.


4. N-[3-[4-[(1-methylethyl)thio]phenoxy]propyl]-octylamine or a pharmaceutically or veterinarily acceptable salt thereof.

5. N[3-[4-[(1-methylethyl)thio]phenoxy]propyl]-octylamine hydrochloride.


20 6. A compound of the formula / as defined in claim 1, substantially as hereinbefore designated by name or formula in any one of Examples 1 to 23.

7. An acid addition salt of a compound of formula / as defined in claim 1.


8. A process for preparing an alkylthiophenoxyalkylamine having formula /:



30 wherein R is hydrogen or C<sub>1</sub> to C<sub>4</sub> alkyl, R<sub>1</sub> is C<sub>1</sub> to C<sub>8</sub> alkyl, R<sub>2</sub> is C<sub>6</sub> to C<sub>12</sub> alkyl, and n is 2 or 3; or a pharmaceutically or veterinarily acceptable acid addition salt thereof, wherein an alkali metal salt of an alkylthiophenol derivative of formula //



40 wherein R and R<sub>1</sub> have meanings hereinabove specified is reacted with 1-bromo-2-chloroethane or 1-bromo-3-chloropropane affording a phenoxyalkyl chloride intermediate of formula ///



50 wherein R, R<sub>1</sub> and n have meanings hereinabove specified and the formula III intermediate is condensed with an amine of the formula IV



55 wherein R<sub>2</sub> has the meaning hereinabove specified; and if desired, the formula I product in free base form is reacted with an acid to form an acid addition salt thereof.

9. A process for preparing an alkylthiophenoxyalkylamine or salt thereof as claimed in claim 1, substantially as hereinbefore described.


60 10. A process for preparing an alkylthiophenoxyalkylamine or salt thereof as claimed in claim 1, substantially as hereinbefore described in any one of Examples 1 to 23.

11. A compound as claimed in claim 1 when produced by a process as claimed in any one of claims 8 to

10.

65 12. A pharmaceutical or veterinary formulation comprising a compound as claimed in any one of claims 1 to 6 or claim 11 formulated for pharmaceutical or veterinary use.

13. A formulation as claimed in claim 12 in the form of a composition comprising the said compound and a pharmaceutically or veterinarily acceptable carrier or diluent.
14. A formulation as claimed in claim 12 or claim 13 in unit dosage form.
15. A formulation as claimed in claim 14 in the form of a tablet, capsule or suppository.
- 5 16. A formulation as claimed in claim 13 in the form of an injectable solution, or elixir, syrup or suspension for oral administration. 5
17. A formulation as claimed in claim 12 and substantially as hereinbefore described.
18. A formulation as claimed in claim 12 and substantially as hereinbefore described in Example 24 or Example 25.
- 10 19. An intermediate for use in the production of a compound as claimed in claim 1 and having the formula 10



- 20 wherein R, R<sub>1</sub> and n are as defined in claim 1. 20